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Summary This study has investigated two of the main problems with radiolabelled antibody imaging, the
formation of circulating immune complexes (I.C.) and the non specific binding of radiolabel to the antibody
molecule.
Patients undergoing immunoscintigraphy with "'In labelled monoclonal antibody ICR2 were divided into
three groups who received either the radiolabelled antibody alone (control, n = 12), the radiolabelled antibody
which was incubated with the chelating agent diethylene triamine pentacetic acid (DTPA) prior to size
exclusion chromatography (n = 6) or whose injectate was treated with DTPA and cold MAb administered
intravenously prior to radiolabelled MAb administration (n = 6). Radiolabelled antibody uptake in abdominal
organs was measured by region of interest analysis using a gamma camera with online computer and that in
tumour and normal tissues by gamma well counting ofbiopsies. Circulating antigen and immune complex was
measured by high pressure liquid chromatography (HPLC).
The sensitivity of tumour imaging and the tumour uptake of radiolabelled antibody was not significantly
different between the groups. Patients with high circulating antigen levels developed high levels of circulating
immune complex but also had high tumour uptakes of radiolabelled antibody. Administration of cold MAb
increased the splenic, but did not effect the tumour uptake of radiolabelled antibody and only minimally
reduced levels of circulating immune complex. Chelate administration reduced the urinary excretion of
radioactivity but increased the liver uptake of radioactivity.
These results have shown that successful antibody imaging can be carried out despite high levels of
circulating antigen, that large doses ofunlabelled antibody are required to prevent immune complex formation
and that removal of non specifically bound "'In does not reduce the liver uptake of radioactivity.
Many studies over the last 10 years have demonstrated that
radiolabelled tumour associated antibodies may be success-
fully used for the imaging of a variety of human cancers
including those of the colon (Chatal et al., 1984), ovary
(Shepherd et al., 1987), breast (Rainsbury et al., 1983), lung
(Chan et al., 1986), skin (Carrasquillo et al., 1987) and bone
(Armitage et al., 1986). These studies have reported the
results of imaging but have not attempted to correlate the
results with the biodistribution of the radiolabelled antibody.
Of the few studies which have specifically analysed the bio-
distribution of radiolabelled antibodies in patients with
cancer (Hnatowich et al., 1985; Rosenblum et al., 1985), none
have explained the localisation of tumours using antibodies
which recognise an antigen present in the circulation and
which therefore forms a circulating immune complex. In-
creasing the dose of administered antibody has been shown
in some studies to improve the quality of images produced
but the mechanism by which this is achieved, and the rela-
tionship to circulating immune complexes, has not as yet
been elucidated (Lamki et al., 1988; Carrasquillo et al., 1988).
Possibly the greatest problem which is encountered in
immunoscintigraphy is the background uptake of the radio-
labelled antibody which results in poor quality images. This
is partly attributable to clearance of the radiolabelled anti-
body by the reticuloendothelial system (RES) and partly due
to instability of the radiopharmaceutical (Halpern et al.,
1983; Goodwin et al., 1986). With antibodies labelled with
charged metallic ions such as Indium-111 ["'In] using a
chelating agent (usually diethylene triamine pentacetic acid
(DTPA)), unstable non specific protein binding may be a
major factor in the background uptake of radioactivity
(Hnatowich & McGann, 1987). This problem is most evident
with the liver which may accumulate 30-40% of the injected
radioactivity (Rainsbury, 1984). The pretreatment of "'In
labelled antibodies with metal chelating agents has been
shown in tissue culture to reduce the uptake of radioactivity
by hepatocytes and may, therefore, improve the results of
immunoscintigraphy (Davidson et al., 1990). This has not
been investigated in human studies.
The present study has analysed the importance of circu-
lating immune complexes to the tumour uptake and biodistri-
bution of a novel "'In labelled monoclonal antibody ICR2.
Immune complex formation and tumour uptake of radio-
labelled monoclonal antibody was examined following
administration of cold unlabelled antibody to avoid the
administered radiolabelled MAb being bound in circulating
immune complex. Secondly the effect of 'scavenging' radio-
label non specifically associated with the MAb was evaluated.
An initial in vitro study on immune complex formation was
carried out and a subsequent clinical study in which the
blood levels, urinary clearance, tumour and normal organ
uptake of the "'In labelled antibody was measured along
with levels of circulating immune complexes and the antigen
expression of the resected tumours. This was then compared
to the images and the biodistribution of the radiolabelled
antibody in further groups of patients in whom the chelating
agent DTPA was administered to the radiolabelled antibody
preparation prior to gel permeation column chromatography,
either with or without cold unlabelled antibody being
administered to the patient prior to the labelled antibody.
Materials and methods
In vitro study on coldantibody administration
The possible effect on immune complex formation of admini-
stering unlabelled antibody to patients prior to injection of
the radiolabelled antibody was investigated using serum sam-
ples from normal controls and colorectal cancer patients.
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These were mixed with unlabelled antibody to give a 1:1, 3:1,
10:1 and 100:1 ratio of unlabelled antibody to the subse-
quently added '25I-ICR2. Following the addition of the radio-
labelled antibody the samples were incubated for 1 h then
analysed by size exclusion HPLC (Zorbax GF250, Du Pont).
Clinical study
Patients
Twenty-two patients undergoing immunoscintigraphy with
Indium-1Il labelled monoclonal antibody ICR2 for known
or suspected colorectal cancer were investigated in the
present study. Clinical details of the patients are given in
Table I.
The patients were divided into three groups. The first
group was administered radiolabelled antibody alone (control
group A), the second group had their injectate treated with
chelating agent during preparation (chelate group B) and the
third group, group C, had the injectate pre-treated with
chelate and in addition the intravenous infusion of 5 mg of
cold unlabelled antibody over the 30min preceding radio-
labelled antibody administration.
Radiolabelled antibody
The rat IgG2a MAb ICR2 (Imrie et al., 1990) was used in
the present study. This antibody was raised in Chester Beat-
tie Hooded rats using defatted human milk fat globule mem-
brane as immunogen. Reactivity of ICR2 with colonic
cancers and an immunohistochemical comparison of its bind-
ing to epithelial membrane antigen (EMA) with an antibody
to carcinoembryonic antigen has been described previously
(Davidson et al., 1988; 1989a).
The MAb ICR2 was conjugated to DTPA using the bicyc-
lic anhydride (ccDPTA) method of Krejcarek and Tucker
(1977). Conjugation of ccDPTA with ICR2 at a 2:1 molar
ratio gave a molar substitution ratio of 0.7:1 and an optimal
immunoreactivity (>85%) as determined with a competitive
binding radioimmunoassay using the epithelial membrane
antigen expressing cell line MCF7 as target.
One milligram of the DTPA-ICR2 conjugate was labelled
with 100-200 MBq of "'In by incubating the conjugate with
"'In acetate pH6 for 20 min. Removal of the unbound "'lIn
Table I Details ofpatients undergoing immunoscintigraphy
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Init.
MD
MB
RS
RN
DN
JL
JH
BT
JP
KH
MJ
BB
VD
FH
BS
RD
JP
EB
DN
DF
GX
JB
Age
60
83
53
66
51
71
79
58
59
65
67
54
74
76
60
64
76
73
73
79
67
56
Diagnosis
Ca
Ca
?recurr
Ca
Ca
Ca
Ca
Ca
Ca
?recurr
Ca
Ca
Ca
Ca
Ca
Lipoma
Ca
Adenoma
Ca
Adenoma
Ca
Ca
Site
R/S
R/S
Hep flex
Hep flex
Rectum
Trans
Rectum
Sigmoid
Sigmoid
Rectum
Sigmoid
Sigmoid
Sigmoid
Sigmoid
Spl flex
Caecum
Sigmnoid
Rectum
R/S
Sigmoid
Treatment
Lt Hemi
Lt Hemi
Laparotomy
Rt Hemi
Rt Hemi
Ant resect.
Lt Hemi
Ant resect.
Lt Hemi
Lt Hemi
Ant resect.
Lt Hemi
Lt Hemi
Lt Hemi
Lt Hemi
Rt Hemi
Lt Hemi
Laser
Ant resect.
Ant resect.
was effected by gel filtration chromatography using a PD10
column (Pharmacia, Upsalla, Sweden). The pooled protein
fractions were then sterilised by micropore filtration through
a 0.25 LM filter (Millipore, France) and subjected to thin
layer chromatography just before use to determine stability
of the "'In label. In order to facilitate the removal of any
"'In which may have been non specifically bound to the
monoclonal antibody (not chelated to the DTPA group)
some samples of the freshly radiolabelled antibody were
incubated with free DTPA (500pLmol for 15 min) prior to gel
filtration chromatography.
The radiolabelled antibody was administered to patients by
an intravenous bolus having excluded their hypersensitivity
by skin testing.
Imaging and organ uptake
Images were obtained of the anterior and posterior abdomen
and pelvic outlet at 10 min and 24, 48 and 72 h after
administration of "'In-ICR2 using a gamma camera (Sie-
mens) fitted with a medium energy collimator and connected
to a computer for data analysis and information storage
(Nodecrest). A positive tumour localisation was assessed as a
focal uptake seen in the images at 24, 48 and 72 h which was
not present on the blood pool image and which corresponded
to a known tumour site on subsequent laparotomy.
The gamma camera was also used to assess the uptake
of radiolabelled antibody in the liver, spleen, kidneys and
bone marrow using an anthropomorphic phantom and
region of interest (ROI) analysis for the liver and ROI
analysis alone for the spleen, kidneys and bone marrow
(Davidson, 1989b).
Determination ofEMA in serum
Normal sera contains EMA or EMA like substances that
bind to ICR2. To determine the amount in the patients sera
a competitive radioimmunoassay was used that is based on
the binding of '25I-ICR2 to plates coated with purified EMA
(Ormerod et al., 1983). Serial dilutions of sera in phosphate
buffered saline containing 0.5% bovine serum albumin (PBS/
BSA) were made in triplicate and 30JAl aliquots of each were
mixed with an equal volume of '25I-ICR2 (105 c.p.m.
MBq-'). Aliquots of 50 ll of the mixture were then transfer-
red to 96 well plates (Nunc) that had been pretreated with
EMA by covering each well with 50 yI of PBS/BSA contain-
ing 5 pgml-I of EMA and then blocking for 1 h at 37°C
with 200 l well of PBS/BSA. Unbound radioactivity was
removed by repeated washing with PBS-BSA and then the
bound '25I-ICR2 detected by counting each well in an Inno-
tron Hydragamma 16 well counter (John Cant, Evesham,
UK). Standard curves were prepared by mixing known con-
centrations of EMA with '25I-ICR2 and incubating with the
EMA coated multiwell plates.
Circulating levels ofimmune complex
The levels ofimmune complex in the serum were measured at
intervals after the administration of radiolabelled antibody
by high performance liquid chromatography (HPLC) on a
Zorbax GF250 (DuPont, Massachussetts). The serum taken
from patients before administration of the radiolabelled anti-
body was also tested by HPLC for immune complex forma-
tion with 125I-ICR2. '25I-ICR2 was added to the serum to give
a concentration of 0.3 igml-l which is equivalent to the
concentration found by administering 1 mg of MAb to a
patient with a plasma volume of 3 litres (blood volume of 5
litres and haematocrit of 40%).
Blood clearance, urinary excretion and tumour uptake
Following administration the clearance of radiolabelled anti-
body from the blood was determined by gamma well count-
ing of paired 2 ml serum samples taken at 10min, 30 min,
24, 48 and 72 h.
No.: number in series; Init.: patients initials; Ca: carcinoma; ?recurr:
suspected recurrent tumour; R/S: rectosigmoid; Hep flex: hepatic
flexure; Trans: transverse colon; SpI flex: splenic flexure; Lt Hemi: left
hemicolectomy; Rt Hemi: right hemicolectomy; Ant resect: anterior
resection.852 B.R. DAVIDSON et al.
The urinary excretion and uptake of radioactivity by the
tumour was calculated as a percentage of the injected dose of
radioactivity (% I.D.) by preparing a known dilution of the
injectate and determining its radioactivity at the same time as
that of the sample of tumour or urine being measured, again
using a gamma well counter.
Results
In vitro analysis
When 1251I or "'In-labelled ICR2 which has been prepared for
in vitro or clinical studies was analysed by HPLC it was
found to elute as a single peak corresponding to a molecular
weight of 150-160,000. When serum samples from either
healthy volunteers or patients with cancer were mixed with
either of the radiolabelled antibodies two peaks eluted from
the column. The first, comprising approximately 30% of the
labelled activity, eluted within the void volume of the column
and had a molecular weight>600,000. The second peak
contained the remainder and corresponded to the molecular
weight expected for IgG (150-160,000).
With all serum samples the amount of high molecular
weight complex formed with radiolabelled antibody was
reduced by first incubating the serum with unlabelled anti-
body. The percentage of 125I or "'In labelled ICR2 present in
the complex was reduced with progressive increase in the
concentration of the cold antibody. In the example shown in
Figure l(a-d) immune complex was reduced from 37.6% of
the total activity at a ratio of unlabelled to labelled of 1:1
(la) to 5.7% at a 100:1 ratio (ld).
Clinical studies
Imaging results
Of the 22 patients to whom radiolabelled MAb was admini-
stered two were not imaged, three had benign tumours and
two were shown not to have recurrent colorectal cancers. Of
the 15 patients with primary cancers the number of tumour
sites localised were not significantly different in control group
(Group A) (five or six +ve), the group given antibody
pretreated with chelate (Group B) (four of six + ve) or the
group pretreated with unlabelled antibody (Group C) (three
of three +ve). Similarly the level of background radio-
activity in the images produced was not found to be different
in an objective assessment by a nuclear medicine clinician.
Blood clearance
The clearance of radioactivity from the blood is shown as a
percentage of the level at 10min in Figure 2. Here, the mean
effective half life of the circulating activity was 39 h for
controls (Group A), 33 h for the Group B given chelate
treated antibody and 27 h for Group C pretreated with cold
antibody. Furthermore the level of radioactivity in the blood
was significantly less in Group B at 48 h (P= 0.005) and in
Group C at both 24 h (P = 0.034) and 48 h (P = 0.000)
compared with controls. We conclude that the rate of
clearance of antibody from the blood was enhanced by pre-
treatment of radiolabelled antibody with DTPA or by pre-
treatment of the patient with unlabelled ICR2.
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Figure 1(a-d) The effect of cold antibody administration on
immune complex formation. HPLC analysis of human serum
following reaction with "'In-ICR2 demonstrated a high mole-
cular weight peak formed by immune complex and a low mole-
cular weight peak formed by monomeric IgG. The effect of
adding cold unlabelled antibody to the serum prior to radio-
labelled MAb administration at concentrations of 1:1 a, 3:1 b,
10:1 c, and 100:1 d are shown. The area under the curve has been
integrated to give the percentage of the total circulating activity
forming the high molecular weight complex.
Time after administration
Figure 2 Blood clearance of radioactivity. The level of radio-
activity in the circulation with time is shown compared with
samples taken at 10 min after radiolabelled MAb administration.
The results are mean±standard deviation for the controls, che-
late and cold antibody groups.
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Urinary excretion
The urinary excretion ofradioactivity was significantly reduc-
ed over the first 12 h period when DTPA treated "'In-ICR2
was administered (16.2 ± 6.94 vs 2.9 ± 1.8% of injected dose,
P = 0.007) but excretion was not affected by the administra-
tion of unlabelled ICR2.
Tumour uptake
The absolute uptake of activity in the tumours as determined
by gamma well counting of specimens obtained at surgery
ranged from 0.0016% I.D. g-' to 0.016% I.D. g- with a
tumour to normal colon ratio of 2.1 ± 0.915 (mean ± s.d.).
There was no significant difference in the value between the
three groups of patients.
Organ uptake ofradiolabelled antibody
By 48 h after administration about 20% of the injected dose
had accumulated in the liver of patients in the control group
A (21.9 + 4.6, Table Ha). An increased percentage of the
injected dose was found to accumulate in the liver ofpatients
in group B given antibody pretreated with DTPA at 45 min
(22.2 ± 2.6 vs 18.1 ± 3.2, P = 0.049), 24 (26.0 ± 4.9 vs 20.7 ±
3.5, P = 0.029) and 48 h (31.6 ± 3.7 vs 21.9 ± 4.6, P = 0.002).
The preadministration of cold MAb to patients in Group C
led to a reduced liver uptake at 48 h (26% vs 32%, P<0.05)
but no significant differences were observed at the earlier
times.
By 48 h after administration 2-3% of the injected dose
had accumulated in the spleen in the control group (2.44 ±
1.4). Analysis of the counts accumulating in the spleen per
MBq of injected activity showed this to be significantly in-
creased in the other groups (Group B, P = 0.05) (Group C,
P<0.05) (Table HIb). No significant differences were found
between the groups regarding the renal uptake or that of the
bone marrow (data not shown).
Analysis ofimmune complexes in vivo
Serum from 16 of the 22 patients undergoing immunoscinti-
graphy were analysed by HPLC. When these sera were react-
ed in vitro with 1251-ICR2, a mean of 31.5 ± 3.6% of the
radioactivity was found in the immune complex of >600kD.
When serum samples taken from the patients were analysed
by HPLC the amount of the high molecular weight cir-
culating immune complex was found to decrease with time
after administration of the radiolabelled ICR2. When 5 mg
of cold MAb was injected before the administration of the
radiolabelled antibody only a small reduction in the quantity
of immune complex was observed from 34.2% to 30.2% of
the circulating radioactivity.
Circulating antigen levels
The apparent levels of EMA in the patients serum varied
from 60-1150 ngml-I with a mean level in the total patient
group of 544 ± 340 ngml-1. No significant differences were
noted between the rate of clearance of "'In-ICR2 from the
blood of patients with low (n =9, <500 ngml-) or high
(n = 6, >500 ngml-') levels of circulating antigen. A strong
correlation was found, however, between the level of EMA in
the patients serum prior to "'In-ICR2 administration and the
amount of immune complex formed following administra-
tion, patients with higher circulating antigen levels forming
greater amounts of circulating immune complex (n =11),
r = 0.61, P<0.05) (Figure 3). Circulating antigen levels also
had a direct correlation with tumour uptake of radiolabelled
antibody (n = 9, r = 0.65, P = 0.05) (Figure 4).
Discussion
This study has shown that when the anti-EMA antibody
ICR2 was injected intravenously into patients with colon
Table II Organ uptake of radioactivity
(a) Liver
Patient group
Time after Control Chelate Cold antibody
administration (A) (B) (C)
45min 18.1±3.2 22.2±2.6a 18.7±6.0
24 h 20.7± 3.5 26.0±4.9b 22.8±4.4
48 h 21.9±4.6 31.6± 3.7c 25.8+4.Od
Organ uptake as a percentage ofthe injected dose (mean±standard
deviation). Statistical comparisonwithcontrols8p = 0.049;bp = 0.029;
cP = 0.002, dCold MAb vs chelate alone P<0.05.
(b) Spleen
Patient group
Tine after Control Chelate Cold antibody
administration (A) (B) (C)
45 min 433±154 603± 124a 815± 157b
24h 470± 159 615±141a 859±l1ob
48 h 450±149 526± 76a 800±143b
Uptake as counts/5 min/MBq of injected activity (mean±standard
deviation). Statistical comparison with controls. ap= 0.05; bp<O.OS.
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Figure 3 Circulating antigen and immune complex formation.
Circulating antigen levels were measured by radioimmunoassay in
serum samples taken prior to radiolabelled MAb administration
and the amount of immune complex formed was calculated by
HPLC of serum following radiolabelled antibody administration.
The relationship is shown between circulating antigen levels and
immune complex formation.
cancer a high molecular weight immune complex was formed
in the blood with antigen or antigen-like material.
Studies in vitro show that the same high molecular weight
complex was formed when the anti-EMA antibody ICR2,
labelled with either "'In or 125I, was mixed with serum from
patients with colon cancer or normal controls. The reduction
in amount of radiactivity present in the high molecular
weight complex by the addition of cold antibody would
suggest that it is a true immune complex.
It would seem likely, although it is rarely reported, that
radiolabelled monoclonal antibodies raised against other
secreted tumour associated antigens (NIH consensus state-
ment 1981; Magnani et al., 1983; Canney et al., 1984;
Nouwen et al., 1985; Chia et al., 1985; Hilkens et al., 1986;
Klug et al., 1986; Ashorn et al., 1988; Ben-Mahrez et al.,
1988) would also form circulating immune complexes when
administered for immunoscintigraphy (Mach et al., 1980a;
Primus et al., 1980; Dillman et al., 1984; Zalutsky et al.,
1988). Although it has been suggested by some authors that
the presence of antigen in the blood does not significantly
affect the results of imaging (Goldenberg et al., 1978; Mach
et al., 1980b) other studies have shown that when an in-
creased dose of antibody has been administered the numbers854 B.R. DAVIDSON et al.
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Figure 4 Circulating antigen levels and the tumour uptake of
radiolabelled MAb. The circulating antigen levels were measured
by radioimmunoassay. Tumour uptake of radiolabelled MAb was
calculated by weighing and gamma well counting biopsies of
resected tumour and comparing the radioactivity per gram to a
standard produced as a known percentage of the injected radio-
activity. The association between circulating antigen in ngml-'
and the tumour uptake as a percentage of the injected dose is
shown.
of tumour sites detected on immunoscintigraphy is increased
(Halpern et al., 1985; Murray et al., 1985; Carrasquillo et al.,
1986). This conflict of opinion on the significant of circu-
lating immune complexes may be explained by differences in
the antigen associated with the tumour and those present in
the circulation and also in their affinity of binding to admin-
istered radiolabelled antibody. Such differences explain varia-
tions in the reported value of administering unlabelled MAb
during immunoscintigraphy.
Based on the in vitro data a group of patients in the
present study were given a small dose (5 mg) of unlabelled
ICR2 prior to injection of the "'In labelled antibody. This
treatment did not, however, result in a significant improve-
ment in the number of tumour deposits localised on imaging,
nor did it enhance the tumour to background ratio of radio-
activity or lead to a greater uptake of radioactivity by the
tumours. This finding contrasts with those of previous studies
where it was concluded that administration of cold antibody
was beneficial. The earlier studies, however, claimed an im-
provement only in the number of tumour deposits localised
in patients with multiple tumours and have not demonstrated
increased tumour uptake of radioactivity (Halpern et al.,
1985; Murray et al., 1985; Carrasquillo et al., 1986).
The biodistribution analysis suggests a reason why the
tumour uptake of radiolabelled MAb was not significantly
increased by the preadministration of unlabelled antibody in
that it was found that the percentage of radioactivity forming
immune complexes in the blood was reduced by only 4%
following administration of 5 mg of unlabelled antibody. A
large dose of cold antibody would therefore be required to
prevent or significantly reduced the formation of immune
complexes. A better understanding of the importance of cir-
culating antigen in immunoscintigraphy would be achieved if
accurate analysis of the biodistribution of radiolabelled anti-
body was performed routinely.
Clearly the problems associated with circulating antigen
need to be overcome. One approach would be to use anti-
bodies to tumour associated antigens which are not secreted
or alternatively antibodies which recognise epitopes not pres-
ent on the secreted antigen molecule.
A correlation was found between the level of circulating
antigen and the uptake of radiolabelled ICR2 into the
immune complexes, those patients with highest levels of cir-
culating antigen having the greatest amount of circulating
immune complex in the blood. However, the strong correla-
tion between the amount of circulating immune complex
present in the blood and the uptake of radioactivity by the
tumour would not have been expected and has not been
reported previously. This finding would suggest that patients
with large amounts of circulating immune complexes and
small amounts of free radiolabelled antibody have the best
uptake of radiolabelled antibody into their tumours. The
relationship between the expression of antigen at the tumour
cell surface ad the amount shed into the circulation is contro-
versial and is likely to vary from one tumour associated
antigen to another (Wagener et al., 1981; Martin & Halpern,
1984; Philben et al., 1986). It is possible that satisfactory
antibody imaging may be achieved despite high levels of
circulating antigen if the tumour associated antigen is
strongly expressed on the cell surface or the affinity of the
antibody was greater for the tumour bound antigen than to
that in the circulation.
The pretreatment of the radiolabelled antibody with che-
late has not been found to be of any value in this clinical
study. The uptake of radiolabelled antibody in the liver and
spleen was greater in the group receiving chelate treated
antibody than in the untreated controls, suggesting that this
uptake of activity is largely due to stable radiolabelled anti-
body rather than dissociated "'In. This result contrasts with
the situation in vitro where a significant reduction in the
uptake of "'In-MAb by hepatocytes was achieved using
chelating agents without reducing the tumour uptake (David-
son et al., 1990). The difference between the results found in
vitro and in the clinical investigation may, however, be due to
differences in the concentration of chelate in the environment
of the hepatocytes, a high local concentration of chelate
being required to prevent the uptake of "'In by hepatocytes.
The concentration required to prevent hepatocyte uptake in
vitro would not be safely obtainable in vivo. Indeed, studies
on the use of chelating agents to inhibit the liver uptake of
radiolabelled antibodies have been carried out in animals but
the results have failed to establish a useful role for this
procedure (Ward et al., 1986).
Before immunoscintigraphy can become routinely employ-
ed there are a number of problems which must be addressed.
Firstly there is a need for antibodies with a greater tumour
specificity so that the uptake by normal tissues is reduced.
Second, it is essential to lower the non specific uptake and
retention of radionuclide by organs such as the liver. Here
the use of Iodine-124 or 99ITc would be expected to lead to
substantial improvements (Goldenberg et al., 1990; Lamki et
al., 1990). The use of bispecific antibodies which recognise
both a tumour antigen and a low molecular weight probe
that may be radiolabelled also offers a number of advantages
(Goodwin et al., 1988), not least that administration of the
radiolabelled probe can be done after antibodies that are non
specifically bound to normal tissue are cleaved from the cell
surface. Other techniques have been employed to improve
immunoscintigraphy, Paik and colleagues (1989) describing
the use of a metabolisable linker joining the MAb with the
radiolabel and showing increased tumour to background
ratios in an animal xenograft model. The use of the bio-
logical linkage of avidin and biotin has also been investigated
although the results of these studies remain preliminary
(Kalofonos et al., 1990). Other methods for optimising
immunoscintigraphy are required along with careful evalua-
tion of the results.
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